Recombinant Human FABP4 protein (His Tag)

种属

Human

纯度

>90 %, SDS-PAGE

标签

His Tag

生物活性

未测试

Cat no : Eg0880

Print datasheet

Synonyms

FABP4, Adipocyte lipid-binding protein, Adipocyte-type fatty acid-binding protein, AFABP, ALBP



产品信息

纯度 >90 %, SDS-PAGE
内毒素 <0.1 EU/μg protein, LAL method
生物活性
Not tested
来源 HEK293-derived Human FABP4 protein Cys2-Ala132 (Accession# P15090) with a His tag at the C-terminus.
基因ID 2167
蛋白编号 P15090
预测分子量 15.7 kDa
SDS-PAGE 13-15 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

Fatty acid binding protein (FABP) 4 is a member of the FABP family which abundantly expressed, fatty acid carrier proteins. FABPs are capable of binding a variety of hydrophobic molecules such as long-chain fatty acids and are important for their uptake and intracellular trafficking. It was first identified as an adipocyte-specific protein, important for the maintenance of lipid and glucose metabolism. It is also detected in macrophages, where it participates in regulating inflammation and cholesterol trafficking via NFκB and PPAR. In more recent studies, FABP4 has been found in a variety of endothelial cells, where it has been identified as a target of VEGF and a regulator of cell proliferation and possibly angiogenesis. Pathologically, FABP4 has been associated with the development of metabolic syndrome, diabetes and cancer and vulnerability of atherosclerotic plaques. FABP4 has been identified as a novel prognostic factor for both adverse cardiovascular events and breast cancer.

参考文献:

1.Lai W, et al. (2022)Eur J Pharmacol. 931:175224. 2.Floresta G, et al. (2022)Eur J Med Chem. 240:114604. 3.Furuhashi M, et al. (2014). Clin Med Insights Cardiol.8 (Suppl 3):23-33. 4.Furuhashi M. (2019) J Atheroscler Thromb. 26 (3):216-232.